BD and Suttons Creek Partner to Help Pharma and Biotech Companies Deliver Combination Products to Market with Confidence

The collaboration brings together consulting, device agnostic testing, and drug delivery expertise to help pharmaceutical and biotech companies reduce risk and navigate complexity for combination products, including biologics and GLP1 therapies

FRANKLIN LAKES, N.J. (April 27, 2026) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Suttons Creek, a BlueRidge Life Sciences company, today announced a strategic, non-exclusive collaboration designed to help pharmaceutical and biotech companies more efficiently navigate the engineering, testing, quality and regulatory complexity associated with combination product development.

Under the collaboration, ZebraSci, BD's device-agnostic combination product testing organization, is complemented by Sutton's Creek combination product development and systems integration expertise. ZebraSci provides objective, data-driven testing services that support informed decision making across feasibility, performance, verification and validation activities.

As pharmaceutical pipelines increasingly include biologics, GLP-1 therapies and other complex drug-device combinations, development teams often face fragmented vendor ecosystems and disconnected workstreams. The ZebraSci and Suttons Creek collaboration is intended to support greater coordination across development activities while preserving customers' flexibility in selecting partners and technologies.

"Combination product development increasingly requires close coordination across strategy, testing and delivery system considerations," said Patrick Jeukenne, Worldwide President, BD Pharmaceutical Systems. "This collaboration brings together complementary expertise from both companies, helping customers reduce development risk and address regulatory considerations while maintaining choice and flexibility in how they move their programs forward.

The BD ZebraSci and Suttons Creek collaboration will help biotech and pharma combination product development teams navigate tight timelines and increasingly complex delivery requirements, especially as biologics and GLP-1 therapies gain traction. By addressing potential gaps and handoffs earlier in the process, the model is intended to support more predictable development pathways and reduce the likelihood of late-stage rework.

"Combination product development spans multiple vendors and siloed workstreams, driving friction, delays, duplication, and regulatory risk," said Carolyn Dorgan, Vice President of Solutions Engineering at Suttons Creek. This fragmentation often drives FDA data requests stemming from misaligned strategy and testing partners-our collaboration enables a more coordinated and efficient path forward."

Under the collaboration, customers will benefit from:

• Earlier alignment across strategy, testing, and delivery device considerations.
• Strengthening integration and coordination across the planning and execution of key Design History File deliverables, which should reduce development and regulatory risks.
• Faster decision-making and fewer delays caused by disconnected vendor handoffs.
• More efficient management of external partners.
• Objective device evaluation supported by ZebraSci's testing expertise.
• Continued flexibility to choose the providers and solutions best suited to their program.

Because Suttons Creek often works with clients early in product planning and development strategy, the collaboration creates an opportunity to introduce testing and delivery considerations sooner-before timing gaps, supplier onboarding issues or misaligned assumptions can delay downstream work. At the same time, ZebraSci can identify customers who would benefit from strategic and development support earlier in the process, creating a more connected model across the combination product lifecycle.

By reducing fragmentation and improving continuity between planning and execution, the collaboration model is intended to help sponsors move from concept to clinical review and ultimately to market with greater efficiency and confidence.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X or Instagram @becton_dickinson.

About Suttons Creek
Suttons Creek, a BlueRidge Life Sciences company, is the premier outsourced device development team for pharma. The firm provides end-to-end managed consulting services for combination product programs, bridging the gap between pharmaceutical companies and the device-side complexities of drug-device products. From strategic planning, QMS setup, and device/vendor selection through clinical development, regulatory approval, commercial launch, and post-market surveillance, Suttons Creek's experts embed within client organizations to ensure reduced time to approval and increased return on investment. Suttons Creek is part of the BlueRidge Life Sciences family of best-in-class companies providing scientific technology and regulatory solutions, real-world evidence solutions, human factors engineering, commercialization consulting, biopharma cold chain engineering, and drug/biologic delivery system development solutions. For more information, visit suttonscreek.com or blueridgelifesciences.com.

About ZebraSci
ZebraSci (a BD company) is a recognized leader in combination product testing, providing device-agnostic testing services including container closure integrity (CCI) testing, device feasibility and performance testing, device comparison studies, and design verification and validation. ZebraSci's laboratories and technical experts support pharmaceutical and biotech clients with objective, data-driven assessments that enable informed device selection and ensure product quality throughout development. For more information, visit zebrasci.com.

Contacts:
Media
Matt Marcus
VP, Public Relations
[email protected]

Investors
Shawn Bevec
SVP, Investor Relations
[email protected]